Glioblastoma is the most frequent primary brain tumor in adults, representing a highly heterogeneous group of neoplasms that are among the most aggressive and challenging cancers to treat. An improved understanding of the molecular pathways has led to the development of various biomarkers and the evaluation of several agents specifically targeting tumor cells and the tumor microenvironment. However, while occasional targeted therapy responses have been documented in patients, to date no targeted therapy has been formally validated as effective in clinical trials. Treatment developments for the glioblastoma are also tested for all brain cancer types.
Sources: Semantic Scholar
Approved treatments
- 131I-chTNT (Vivatuxin) (glioblastoma)
- 32P-Colloidal Chromic Phosphate (brain cancer)
- 131I-Iobenguane (MIBG) (neuroblastoma)
About Brain Cancer
- What is Glioblastoma? – Brain Tumour Charity
Clinical trials
*non-exhaustive list
Patient associations
Europe: CAN CÉ-TU? (BEL), Brainstrust (GBR), The Brain tumour charity (GBR)
North America: American Brain Tumor Association (USA), National Brain Tumor Society (USA), National Brain Tumor Society (USA)
Worldwide: Accelerate Brain Cancer Cure (ABC2), International Brain Tumour Alliance (IBTA), Brain Tumor Foundation